Eisai to Present the Latest Data on Long-Term, Real-World Treatment with Lecanemab at the AD/PD(TM) 2026 Annual Meeting

TOKYO, Mar 11, 2026 – (JCN Newswire) – Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) announced today the company will present the latest findings on lecanemab (generic name, U.S. brand name: LEQEMBI®), Eisai’s anti-amyloid beta (Aβ) protofibril antibody for the treatment of Alzheimer’s disease (AD…
Read More